Paul Calabresi Scholars Matthew Goetz, M.D.
Award: July 2003 to present Projects - Tamoxifen CYP2D6 pharmacogenetics
- UGT1A1 and irinotecan pharmacogenetics
- Gene expression profiling for prediction of tamoxifen resistance
- Molecular markers for the determination of invasive recurrence in surgically treated DCIS
- Mutational analysis of the epidermal growth factor receptor and stem cell factor receptor genes in metaplastic breast carcinoma
Mentors Publications 2006-2007 - Pruthi S, Boughey JC, Brandt KR, Degnem AC, Dy GK, Goetz MP, et al: A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clinic Proceedings, 2007; 82:1131-40.
- Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, et al: Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clinical Colorectal Cancer, 2007; 6:572-7.
- Pruthi S, Brandt KR, Degnem AC, Goetz MP, Perez EA, Reynolds CA, et al: A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clinic Proceedings, 2007; 82:999-1012.
- McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, et al: Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clinical Colorectal Cancer, 2007; 6:516-21.
- Goetz MP, Ingle JN, Couch FJ: Gene-expression-based predictors for breast cancer. New England Journal of Medicine, 2007; 356:752; author reply.
- Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch F, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez E, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment, 2007; 101(1):113-21.
- Callstrom MR, Atwell TD, Charboneau JW, Farrell MA, Goetz MP, Rubin J, et al: Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis. Radiology 241:572-80, 2006
- Bardia A, Loprinzi CL, Goetz MP: Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. Journal of Clinical Oncology, 2006; 24:e18-9.
- Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clinical Cancer Research, 2006; 12:2080-7.
- Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, et al: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Research and Treatment, 2006; 98:217-22.
David Steensma, M.D.
Award: September 2004 to present Projects - Myelodysplastic syndromes -- a group of related malignant hematopoietic stem cell disorders that are incurable with currently available therapies short of allogeneic hematopoietic stem cell transplantation
Mentors Publications 2006-2007 - Steensma DP, Tefferi A. Risk-Based Management of Myelodysplastic Syndrome. Oncology 2007; 21(1): 43-54.
- White JG, Nichols WL, Steensma DP. Platelet Pathology in Sex-Linked GATA-1 Dyserythropoietic Macrothrombocytopenia I Ultrastructure. Platelets, 2007; 18(4):273-83.
- Phillips JD, Steensma DP, Spangrude G, Pulsipher M, Kushner JP. Congenital Erythropoietic Porphyria Associated with a GATA1 Mutation: The First Trans-Acting Mutation Causing Human Porphyria. Blood, 2007; 109(6) 2618-21.
- Caudill JC, Sood R, Zehnder JL, Pruthi RK, Steensma DP. Severe Coagulation Factor V Deficiency Associated with an Interstitial Deletion of Chromosome 1Q. Journal of Thrombosis and Haemostasis, 2007; 5(3): 626-8.
- Baumann Kreuziger LM, Porcher JC, Ketterling RP, Steensma DP. An MLL-SEPT9 Fusion and t(11;17)(q23;q25) Associated With De Novo Myelodysplastic Syndrome. Leukemia Research, 2007; 31(8): 1145-1148.
- Steensma DP, Kyle RA. A History of the Kidney in Plasma Cell Disorders. Contributions in Nephrology, 2007; 153: 5-24.
- Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and Cytogenetic Response to Lenalidomide Monotherapy in Acute Myeloid Leukemia Arising From JAK2(V617F) Positive, Del(5)(q13q33) Myelodysplastic Syndrome. Leukemia, 2006; 20(11): 2063-4.
- Steensma DP. JAK2 V617F in Myeloid Disorders: Molecular Diagnostic techniques and Their Clinical Utility: A Paper From the 2005 William Beaumont Hospital Symposium on Molecular Pathology. Journal of Molecular Diagnostics, 2006; 8(4):397-411.
- Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HE, Dewald G, Kaufmann SH. JAK2 V617F Is Rare In De Novo Acute Myeloid Leukemia, But STAT3 Activation Is Common And Remains Unexplained. Leukemia, 2006; 20(6): 971-978.
- Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus Kinase 2 (V617F) Mutation Status, Signal Transducer And Activator of Transcription-3 Phosphorylation And Impaired Neutrophil Apoptosis In Myelofibrosis With Myeloid Metaplasia. Leukemia, 2006; 20(10):1800-8.
- Steensma DP, Hecksel K, Porcher JC, Lasho TL. Candidate Gene Mutation Analysis in Idiopathic Acquired Sideroblastic (Refractory Anemia With Ringed Sideroblasts). Leukemia Research, 2007; 31(5):623-8.
- Thompson CA, Steensma DP. Pure Red Cell Aplasia Associated With Thymoma: Clinical Insights from 50-Year Single Institution Experience. British Journal of Haematology, 2006; 135(3): 405-7.
- Pardanani A, Levine RL, Lasho TL, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 Mutations in Myeloproliferative And Other Myeloid Disorders: A Study of 1182 Patients. Blood, 2006; 108(10): 3472-6.
- Caudill JSC, Sternberg AS, Lasho TL, Tefferi A, Steensma DP. C-Terminal Nucleophosmin Mutations Are Uncommon In Chronic Myeloid Disorders. British Journal of Haematology, 2006; 133(6): 638-41.
- Thurmes PJ, Steensma DP. Elevated Serum Erythropoietin Levels in Patients with Budd-Chiari Syndrome Secondary to Polycythemia Vera: Clinical Implications for the Role of JAK2 Mutation Analysis. European Journal of Haematology, 2006; 77(1): 57-60.
- Knox S, Kurtin PJ, Steensma DP. Isolated Splenic Sinus Histiocytosis (Rosai-Dorfman Disease) In Association With Myelodysplastic Syndrome. Journal of Clinical Oncology, 2006; 24(24): 4027-8.
- Costa DB, Fisher CA, Miller KB, Pihan GA, Steensma DP, Gibbons RJ, Higgs DR. A Novel Mutation in the Last Exon of ATRX in a Patient with Alpha-thalassemia Myelodysplastic Syndrome. European Journal of Haematology, 2006; 76(5): 432-5.
- Steensma DP. Are Myelodysplastic Syndromes "Cancer"? Unexpected Adverse Consequences Of Linguistic Ambiguity. Leukemia Research, 2006; 30(10): 1227-33.
- Steensma DP. Working Against the Grain. Annals of Internal Medicine, 2006; 144(9): 697-8.
- Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM Jr, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL, North Central Cancer Treatment Group. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients with Cancer. Journal of Clinical Oncology, 2006; 24(7): 1079-89. Selected for editorial comment.
- Nelson MA, Steensma DP. JAK2 V617F In Myeloid Disorders: What Do We Know Now, And Where Are We Headed? Leukemia and Lymphoma, 2006; 47(2): 177-94.
- Steensma DP. Luis Walter Alvarez: Another "Mayo-Trained" Nobel Laureate. Mayo Clinic Proceedings, 2006; 81(2): 241-4.
- Steensma DP, Bennett JM. The Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006; 81(1): 104-30.
Kimberly Kalli, Ph.D.
Award: July 2006 to present Projects - Determine whether a multi-peptide vaccine targeting folate receptor alpha (FR) is safe and effective in generating FR-specific immune responses in women in remission from breast or ovarian cancer.
Mentors Publications 2006-2007 - Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, and Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. Journal of Clinical Oncology, 2006; 24:4254-61.
- Ogata Y, Hepplemann CJ, Charlesworth MC, Madden BJ, Miller MN, Kalli KR, Cliby WA, Bergen HR, Saggese DA, and Muddiman DC. Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. Journal of Proteome Research, 2006; 5:3318-3325.
- Haluska P, Carboni JM, Loegering DA, Lee FY, Saulnier M, Frennesson D, Attar R, Kalli KR, Conover CA, Kaufmann SH, Gottardis M, Erlichman C. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-1/insulin receptor inhibitor, BMS-554417. Cancer Research, 2006; 66 (1): 362-71.
Sean Dowdy, M.D.
Award: July 2006 to present Projects - Epigenetic changes in uterine cancer and use of epigenetic inhibitors as possible therapeutics.
Mentors Publications 2006-2007 - Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology, 2006; 107(1):77-85.
- Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecologic Oncology, 2006; 100(2):283-7.
- Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, Podratz KC. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: Technique and analysis of outcomes. Gynecologic Oncology, 2006; 101(2):280-6.
- Mariani A, Dowdy SC, Cliby WA, Haddock MG, Keeney GL, Lesnick TG, Podratz KC. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecologic Oncology, 2006; 101(2):200-8.
- Xiong Y, Dowdy SC, Podratz KC, Jiang SW. et al hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecologic Oncology, 2006; 103(1):321-8.
- Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Molecular Cancer Therapeutics. 2006; 5(11):2767-76.
- Aletti GD, Dowdy S, Podratz KC, Cliby WA. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. American Journal of Obstetrics and Gynecology. 2006 Dec;195(6):1862-8.
- Axtell AE, Lee M, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver J, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider CH. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. Journal of Clinical Oncology, 2007; 25(4):384-9.
- Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: Rationale use of a triage system. Gynecologic Oncology, 2007; 105(1):84-9.
- Jiang S, Dowdy SC, Meng XW, Podratz KC, Jiang SW. Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecologic Oncology, 2007. 105(2):493-500.
- Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecologic Oncology, 2007; 107(2):186-9.
- Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecologic Oncology, 2007; 107(2):190-3.
- Zhou, C, Dowdy SC, Podratz KC, Jiang SW. Epigenetic considerations for endometrial cancer prevention, diagnosis, and treatment. Gynecologic Oncology, 2007; 107(1):143-153.
Julian Molina, M.D., Ph.D.
Award: July 2006 to present Projects - Targeted therapeutics; development of relevant preclinical models to study targeted therapeutics
Mentors Publications 2006-2007 - Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. Journal of Thoracic Oncology, 2006; 1(1):7-9.
- Osborn NK, Zou HZ, Molina JR, Lesche R, Lewin J, Lofton-Day C, Klatt KK, Harrington JJ, Burgart LJ, Ahlquist DA. Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. Clinical Gastroenterology and Hepatololgy, 2006; 4(2):212-8.
- Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. American Journal of Clinical Oncology, 2006; 29(3):246-51.
- Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, Adjei AA. A phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Cancer Investigation, 2006; 24(4):382-9.
- Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest, 2006; 130(4):1211-9.
- Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J, Shridhar V. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene. 2007; 19; 26(34):4969-78
Irina Kovtun, Ph.D.
Award: July 2006 to present Projects - DNA repair and outcome in ovarian cancer
- DNA repair and adverse events in elderly cancer patients
- Biological significance of genes identified by gene expression profiling of prostate cancer tissue
- A survey of prostate cancer advocates for their thoughts on the prostate cancer research agenda
Mentors Publications 2006-2007 Paul Haluska, M.D.
Award: July 2006 to present Projects - Insulin-like growth factor 1 receptor (IGF-1R) inhibition in ovarian and breast cancer; potential synergy of IGF inhibition with pan human epidermal growth factor receptor (HER) inhibition
Mentors Publications 2006-2007 - Haluska P, Carboni JM, Loegering DA, Lee FY, Saulnier M, Frennesson D, Attar R, Kalli KR, Conover CA, Kaufmann SH, Gottardis M, Erlichman C. In Vitro and In Vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-1/Insulin Receptor Inhibitor, BMS-554417. Cancer Research, 2006; 66 (1): 362-71.
Michael Menefee, M.D.
Award: February 2007 to present Project - Investigation of combinatorial therapy with inhibitors of the mammalian target of rapamycin (mTOR) and the epothilone B analog ixabepilone
Mentors Past Paul Calabresi Scholars include: Sadhna Kohli, Ph.D.
Award: July 2008 to present Project - Screening cancer populations who may develop treatment-related cognitive impairment, using novel diagnostic tools such as Magnetic Resonance Spectroscopy and standard neuropsychological testing
- Generate estimates of cognitive decline in a specific patient population
- Plan for subsequent controlled intervention trials examining the efficacy of neuro-protective agents
Mentors Shaji Kumar, M.D.
Award: July 2008 to present Project - Test the hypothesis that targeting the effect of VEGF in myeloma will allow other therapies to be more effective
- Clinical trials to determine the importance of VEGF in the pathology of this disease, and the ability of VEGF blockade to enhance the efficacy of currently available myeloma therapies
- Correlative studies to better understand the mechanisms involvedIn addition, ongoing work will focus on identifying other mechanisms that mediate the talk between myeloma cells and the microenvironment, some of which will be amenable to therapeutic targeting.
Mentors Publications 2006-2007 Harry Yoon, M.D.
Award: July 2008 to present Project - Identification of prognostic and predictive markers to help guide clinical management in esophageal cancer
- Investigating polymorphisms and loss of heterozygosity in DNA repair genes
- Investigate markers related to methylation and micro RNA
Mentors |
